Ventoxen is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML).
Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It works by blocking the action of a certain protein in the body that helps cancer cells survive.
Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia.
Ventoxen is a generic version of Venclexta which is Venetoclax indicated for AML & CLL/SLL.
As a Least Developed Country (LDC), Bangladesh received a special waiver under the WTO’s TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) until 2033. This allows Bangladesh to produce generic versions of patented drugs without paying royalties, significantly reducing manufacturing costs.
Ventoxen tablets should be taken orally once daily with food, following your healthcare provider’s exact instructions.
No. As a commitment to patient affordability, Everest Pharmaceuticals Ltd. proudly introduces Ventoxen, the first global generic version of Venetoclax (Venclexta). This medication is now accessible to patients worldwide at a more affordable price. Contact us to learn more about availability and purchasing options.
This medicine may cause serious infections, including pneumonia (lung infection) and sepsis (blood infection), which can be life-threatening. Check with your doctor if you have symptoms of an infection such as a fever, chills, body aches, or sore throat.
